{"id":"W4396590541","doi":"10.1158/1538-7445.sabcs23-gs01-02","title":"Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Oncology; Breast cancer; Adjuvant; Internal medicine; Chemotherapy; Cancer; Stage (stratigraphy); Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001839997,0.002316035,0.00203068,0.0006674379,0.0005807973,0.001208246,0.001395524,0.001615806,0.01377905],"category_scores_gemma":[0.0008438491,0.0008283155,0.001652999,0.0006396009,0.00147205,0.001032089,0.000510802,0.004326471,0.002566115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001387578,"about_ca_system_score_gemma":0.003075516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001570266,"about_ca_topic_score_gemma":0.005531298,"domain_scores_codex":[0.9995027,0.0002482089,0.00002195695,0.0000846312,0.00004706264,0.00009554945],"domain_scores_gemma":[0.9994227,0.0000642173,0.0001119909,0.00005661971,0.00003658629,0.0003079986],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8895478,0.05558497,0.001148776,0.0007058533,0.001103962,0.0000773401,0.00008493871,0.0009681421,0.02207174,0.0002455157,0.005133782,0.02332712],"study_design_scores_gemma":[0.8143616,0.1804595,0.001994134,0.00002268848,0.0002821442,0.00004885844,0.0000257984,0.0002565166,0.001099652,0.0001439854,0.00128847,0.0000167531],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9660065,0.002732345,0.001163705,0.00124735,0.0006487764,0.01359415,0.007701575,0.0004970078,0.006408545],"genre_scores_gemma":[0.9553421,0.002299429,0.003781632,0.003916121,0.0004415321,0.01355444,0.009754464,0.0001218531,0.01078841],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01377905,"threshold_uncertainty_score":0.04609549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05671915275095064,"score_gpt":0.4144835822188015,"score_spread":0.3577644294678509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}